
Experience
ACELYRIN Announces Pricing of Upsized Initial Public Offering
May 15, 2023
Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.
Related contacts
Related Practices & Industries
Structure Therapeutics – $185.3 Million IPO
February 9, 2023
San Francisco – February 9, 2023 – Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.
The offering marks the first sizable US life sciences IPO this year. Structure Therapeutics will use the proceeds to develop new oral therapies for the treatment of various diseases, including those impacting the metabolic, cardiovascular and pulmonary systems. Its lead product candidate targets Type 2 diabetes and obesity.
Structure Therapeutics aims to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling it to build a pipeline of product candidates. The company currently focuses on G-protein-coupled receptors as a therapeutic target class.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
Related contacts
Related Practices & Industries
Oyster Point Pharma to Be Acquired by Viatris
November 10, 2022
Cooley advised Oyster Point Pharma, a top ophthalmology-focused biopharmaceutical company, on its definitive agreement to be acquired by global healthcare company Viatris. Partners Mika Reiner Mayer, Brandon Fenn, Div Gupta and Ian Nussbaum led the Cooley team advising Oyster Point Pharma.
Related contacts
Related Practices & Industries
Thoma Bravo’s Instructure Agrees to Sell Employee Development Platform Bridge to Learning Technologies Group
March 3, 2021
Cooley advised Instructure, a Thoma Bravo-owned education technology company, on its agreement to sell Bridge, an employee learning, performance and skills development platform, to Learning Technologies Group. Lawyers Matt Hemington, David Silverman, Anna Maria Galinska, Caitlin Breitenbruck and Steve Tonsfeldt led the Cooley team advising Instructure.
Related contacts
Related Practices & Industries
Instructure Sells to Thoma Bravo for $2 Billion
December 6, 2019
Cooley advised publicly traded education technology company Instructure on its agreement to sell to private equity firm Thoma Bravo. The transaction, which values Instructure at approximately $2 billion, is expected to close in Q1 2020. Cooley lawyers Matt Hemington, Steve Tonsfeldt, David Silverman and Ian Nussbaum led the team advising the company.
Related contacts
Related Practices & Industries
Related news and events
Memberships & affiliations
American Bar Association
National Association of Stock Plan Professionals
San Diego County Bar Association